BioUniversa Srl
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
BioUniversa Srl - overview
Established
2009
Location
-, -, Italy
Primary Industry
Medical Devices & Equipment
About
BioUniversa Srl is a biotechnology company focused on developing innovative solutions for health and wellness through research and proprietary biopharmaceutical products designed for personalized medicine. Founded in 2009 and headquartered in Italy, BioUniversa Srl specializes in biotechnology solutions. The company was co-founded by Michele Petrone and Roberto Parente. Giovanni Rizzo is the current CEO.
In November 2010, BioUniversa raised EUR 3. 5 mn in VC funding from Vertis Venture, with participation from TTventure fund, targeting further development of their biotechnology offerings. BioUniversa Srl specializes in the development and provision of innovative biotechnology solutions aimed at enhancing health and wellness through advanced research and product offerings. Their proprietary biopharmaceuticals address various health conditions, emphasizing personalized medicine, chronic disease management, and preventative health measures.
The company serves a diverse clientele, including healthcare providers, research institutions, and direct consumers, primarily in North America and select markets in Europe and Asia. In 2022, BioUniversa Srl generated a revenue of EUR 30,346. 20 and reported an EBITDA of EUR -193,230. 90.
The company earns revenue through direct sales of its biotechnology solutions and partnerships with healthcare organizations, primarily employing a B2B model with long-term contracts and subscription-based access for clients. BioUniversa Srl plans to utilize its recent funding of EUR 3. 5 mn from November 2010 to support the development and launch of new biopharmaceutical products aimed at specific health conditions. The company is targeting expansion into additional European markets and select Asian regions by 2025, aiming to enhance its market presence and accessibility to its innovative healthcare solutions.
Current Investors
Vertis
Primary Industry
Medical Devices & Equipment
Sub Industries
Therapeutic Devices, Diagnostic Equipment
Website
www.biouniversa.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
BioUniversa Srl - timeline of key events
BioUniversa Srl - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | 66,033 | 15,044 | 1,850 | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | (77.2%) | (87.7%) | (100.0%) | - | - | - |
| EBITDA (USD) | (12,088) | (75,745) | (58,811) | (75,537) | (146,710) | (142,297) | 31,227 | 176,541 | (22,779) | (567,056) | - | - | - |
| Operating Income (USD) | (12,857) | (94,644) | (136,586) | (164,335) | (211,266) | (309,459) | (220,540) | (109,941) | (334,329) | (964,921) | - | - | - |
| Operating Margin | - | - | - | - | - | - | (334.0%) | (730.8%) | (18071.8%) | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | 47.3% | 1173.5% | (1231.3%) | - | - | - | - |
| NET Income (USD) | (9,631) | (74,642) | (107,720) | (132,916) | (147,322) | (252,393) | (187,786) | (92,109) | (271,001) | (1,469,868) | - | - | - |
| % Net Margin | - | - | - | - | - | - | (284.4%) | (612.3%) | (14648.7%) | - | - | - | - |
BioUniversa Srl - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.